Researchers at the University of California, San Diego School of Medicine, with colleagues at the University of Rochester Medical Center, have identified a new mechanism that appears to suppress tumor growth, opening the possibility of developing a new class of anti-cancer drugs. … Read the full story from the UCSD Newsroom
Senior author of the study report in the Proceedings of the National Academy of Sciences is Willis X. Li, PhD, professor of medicine in the Division of Pulmonary & Critical Care Medicine and faculty member in the Biomedical Sciences graduate program.
Li’s UC San Diego Department of Medicine coauthors are postdoctoral fellow Pranabananda Dutta, PhD; pulmonary/critical care physician-scientist Jinghong Li, MD, PhD, and senior undergraduate student Jingtong Wang.
Coauthors Xiaoyu Hu, Amy Tsurumi and Hartmut Land are colleagues at the University of Rochester, where Li was a faculty member and researcher at the Wilmot Cancer Center before he joined the faculty at UC San Diego.
At the University of Rochester, LI received the 2008 Davey Memorial Award for Outstanding Cancer Research for his work in the cellular and molecular signaling in cancer development.
He is now principal investigator of an R01 research grant from the National Cancer Institute for the project, Epigenetic Tumor Induction by Heterochromatin Instability.
Citation for the study report:
Xiaoyu Hu, Pranabananda Dutta, Amy Tsurumi, Jinghong Li, Jingtong Wang, Hartmut Land, and Willis X. Li. Unphosphorylated STAT5A stabilizes heterochromatin and suppresses tumor growth. PNAS 2013 ; published ahead of print June 3, 2013, doi:10.1073/pnas.1221243110 | Abstract | Full text (PDF)